Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies

• Published in: Journal of blood medicine 2020-01, Vol.11, p.439-448
• Main Authors: Yang, Renchi, Zhao, Yongqiang, Wang, Xuefeng, Sun, Jing, Wu, Runhui, Jin, Chenghao, Jin, Jie, Wu, Depei, Rendo, Pablo, Sun, Feifei, Rupon, Jeremy, Huard, Francois, Korth-Bradley, Joan M, Xu, Lihong, Luo, Binyu, Liu, Yingxue Cathy
• Format: Article
• Language: English
• Subjects: asian; blood coagulation factor viii; Blood diseases; Care and treatment; Children & youth; deficiency; Drug dosages; Factor VIII; Hemophilia; Hospitals; Laboratories; Original Research; Patients; Pharmaceutical industry; refacto; Surgery; xyntha
• ISSN: 1179-2736; 1179-2736
• DOI: 10.2147/JBM.S241605

Moroctocog alfa albumin-free cell culture (AF-CC) increases plasma levels of factor VIII (FVIII) activity and, in China, is indicated for the control and prevention of bleeding episodes in patients with hemophilia A. This study aimed to evaluate the efficacy, safety, and recovery data of moroctocog alfa (AF-CC) in patients with hemophilia participating in two open-label studies, both conducted in China. The authorization study (clinicaltrials.gov identifier NCT00868530) enrolled patients aged ≥6 years, previously treated with ≥1 exposure day of FVIII replacement therapy. The real-world study (clinicaltrials.gov identifier NCT02492984) enrolled patients of any age who were previously untreated or requiring surgical prophylaxis. In both studies, on-demand treatment was administered over 6 months. Key assessments included response to treatment, FVIII inhibitor development, and recovery. In the authorization study (N = 53; mean age, 23.2 years; severe hemophilia, 23%), response was excellent/good for 90% of infusions at 24 hours. Seven patients developed inhibitors. Mean (SD) FVIII recovery at the initial and final visits was 1.77 (0.50) and 1.67 (0.45) (IU/dL)/(IU/kg), respectively. In the real-world study (N = 85; mean age, 9.5 years; severe hemophilia, 58%), response was rated as excellent or good for most (87%) on-demand infusions and for all surgical prophylaxis patients (n = 14). Seven patients developed FVIII inhibitors. Mean (SD) FVIII recovery at the initial and final visits was 1.71 (0.50) and 1.68 (0.31) (IU/dL)/(IU/kg), respectively. No new safety signals were observed in either study. On-demand treatment and surgical prophylaxis with moroctocog alfa (AF-CC) is safe and effective for both previously treated and previously untreated Chinese patients with hemophilia A.